---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-032826"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T15:50:07.602145+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tenaya reports Q4 net loss $29.9M; cash $104.6M; TN-201 data and TN-401 dosing expected H2 2024

## Summary
- Net loss $29.9M ($0.40/sh) Q4 2023; full year net loss $124.1M ($1.68/sh).
- Cash, equivalents and investments $104.6M at Dec 31, 2023; Feb 2024 financing adds $46.5M net, extending runway into H2 2025.
- Initial safety and biomarker data from MyPeak-1 Phase 1b of TN-201 for MYBPC3 HCM expected H2 2024; first patient dosed Oct 2023.
- RIDGE-1 Phase 1b of TN-401 for PKP2 ARVC on track to dose first patient H2 2024; FDA Fast Track granted Nov 2023.

## SEC filing metadata
- accession: 0000950170-24-032826
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017024032826/0000950170-24-032826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017024032826/tnya-20240318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-032826
- JSON: https://secwatch.observer/filing/0000950170-24-032826.json
- Plain text: https://secwatch.observer/filing/0000950170-24-032826.txt

## Key facts
- Earnings Releases
  Tenaya Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $29.9 million, or $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, n, EPS $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, net loss was $124.1 million, or.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: Net loss was $29.9 million, or $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, n
  - EPS: $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, net loss was $124.1 million, or
  - Result: reported results
  source text: Net loss was $29.9 million, or $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, net loss was $124.1 million, or $1.68 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000095017024032826/0000950170-24-032826-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.